Articles

Next-Generation Sequencing Patents: How to Prepare Compliant Sequence Listings?

If you are filing a next-generation sequencing patent, one of the most critical steps you cannot afford to overlook is preparing a compliant sequence listing. As genomic technologies advance rapidly, patent offices worldwide are tightening their requirements for how biological sequences must be disclosed in patent applications. A poorly prepared sequence listing can delay your patent, lead to rejection, or even result in loss of intellectual property rights. This guide is designed to walk you through everything you need to know, in simple and clear language, so that your next-generation sequencing patent application stands on solid ground from day one.

What Is a Sequence Listing and Why Does It Matter for NGS Patents?

A sequence listing is a standardized, structured document that lists all nucleotide and amino acid sequences claimed or disclosed in a patent application. For any next-generation sequencing patent, this document is not optional. It is a mandatory part of the application whenever sequences of 10 or more nucleotides or 4 or more amino acids are included.

Patent offices, including the USPTO, EPO, and WIPO, require this document to be filed in a specific electronic format. The primary reason is uniformity. When thousands of sequence-based patent applications are filed globally every year, patent examiners and databases need a consistent way to search, compare, and evaluate these sequences.

For next-generation sequencing patents specifically, the challenge is amplified. NGS technologies such as whole-genome sequencing, RNA-Seq, ChIP-Seq, and metagenomics generate enormous volumes of sequence data. A single patent application may contain hundreds or even thousands of individual sequences, making accurate and compliant listing all the more important.

Understanding WIPO ST.26: The New Global Standard

The most important regulatory update affecting next-generation sequencing patent filings in recent years is the adoption of WIPO Standard ST.26. This standard replaced the older ST.25 format and became mandatory for all international patent applications filed via the PCT (Patent Cooperation Treaty) on or after July 1, 2022.

If you are preparing a next-generation sequencing patent today, you must use ST.26 exclusively. Here is what you need to understand about this standard:

XML-based format: Unlike ST.25, which used a plain text format, ST.26 requires sequences to be submitted as structured XML files. This allows better machine readability and database integration.
Separate handling of DNA and RNA: ST.26 requires that DNA and RNA sequences be listed separately, even if they represent the same genetic region. This is a key difference from the old standard.
Mandatory organism information: The source organism for each sequence must now be identified using approved scientific nomenclature wherever possible.
Feature annotations: ST.26 requires biological features of sequences (such as coding regions, promoters, or binding sites) to be annotated within the XML file using standardized feature keys from established biological databases.
WIPO Sequence tool: WIPO provides a free software tool called “WIPO Sequence” to help applicants prepare ST.26-compliant XML files. Using this tool reduces formatting errors significantly.

Failing to comply with ST.26 requirements in a next-generation sequencing patent application can result in the sequence listing being considered as not filed, which is a serious consequence that can delay or invalidate your patent.

Step-by-Step Guide to Preparing a Compliant Sequence Listing for NGS Patents

Preparing a sequence listing for a next-generation sequencing patent requires careful planning, technical knowledge, and attention to detail. Below is a practical, step-by-step breakdown of the process.

Step 1: Identify All Sequences That Require Listing

Review your patent claims and description thoroughly. Every nucleotide sequence of 10 or more bases and every amino acid sequence of 4 or more residues that is disclosed or claimed must be included in the sequence listing. For NGS-based inventions, this often includes primer sequences, probe sequences, reference genome segments, variant sequences, and expressed protein sequences.

Step 2: Assign Sequence Identification Numbers (SEQ ID NOs)

Each sequence must be assigned a unique sequential number, starting from SEQ ID NO: 1. These numbers must be consistently referenced throughout the patent specification and claims. Inconsistencies between SEQ ID NOs in the description and in the listing are a common reason for office actions in next-generation sequencing patent applications.

Step 3: Collect Required Biological Metadata

For ST.26 compliance, you need to gather the following information for each sequence:

Sequence type (DNA, RNA, or protein)
Source organism with correct scientific name
Relevant biological features and their positions within the sequence
Any modifications (such as synthetic sequences or chimeric constructs)

Step 4: Use WIPO Sequence Software to Build Your XML File

Enter all your sequences and metadata into the WIPO Sequence tool. This software validates your entries in real-time and flags formatting errors before you submit. It also generates the final XML file that you will attach to your patent application.

Step 5: Validate and Cross-Check Before Filing

Before submitting your next-generation sequencing patent application, run the XML file through the patent office’s own validation tools (USPTO’s Patent Center or EPO’s online filing system). Double-check that every sequence mentioned in the claims appears in the listing, and vice versa.

Common Mistakes to Avoid in NGS Sequence Listings

Even experienced patent practitioners make errors when handling next-generation sequencing patent sequence listings. Being aware of these pitfalls can save you significant time and cost.

Using the outdated ST.25 format for applications filed after July 2022 is a fundamental error that leads to automatic non-compliance.
Omitting synthetic or modified sequences is another frequent issue. Just because a sequence does not occur naturally does not exempt it from the listing requirement.
Incorrect sequence length counts often arise in NGS data due to copy-paste errors or software export issues. Always verify the length and integrity of each sequence independently.
Missing or incorrect feature annotations in the XML file can trigger objections from examiners, especially for next-generation sequencing patents involving complex genomic constructs.
Inconsistent SEQ ID referencing between the patent description, claims, drawings, and the sequence listing creates confusion and leads to office actions.

Tips for Handling Large-Scale NGS Sequence Data in Patents

Next-generation sequencing patent applications often involve datasets that are far larger than traditional sequence patents. Here are some expert tips for managing this complexity:

Prioritize claim-relevant sequences. Not every sequence generated during NGS research needs to be in the patent. Focus on sequences that are directly tied to the claimed invention, such as novel biomarkers, therapeutic targets, or diagnostic probes.

Use bioinformatics tools for sequence verification. Before including sequences in the listing, run them through tools like NCBI BLAST to verify their identity and uniqueness. This also helps you frame novelty and non-obviousness arguments in your patent specification.

Work with a qualified sequence listing specialist. Given the technical complexity of preparing ST.26-compliant files for large next-generation sequencing patent applications, collaborating with specialists who understand both the science and the legal requirements is highly recommended.

Maintain version control. NGS patent applications go through multiple drafts. Keep clear records of which version of the sequence listing corresponds to which draft of the application to avoid filing the wrong file.

Jurisdiction-Specific Considerations for NGS Patents

While WIPO ST.26 is the global standard, each jurisdiction has additional rules that affect next-generation sequencing patent filings.

In the United States, the USPTO requires the sequence listing to be submitted as an XML file for applications filed on or after July 1, 2022, with the file named according to specific conventions. The USPTO also permits the sequence listing to serve as both the paper and electronic copy when filed properly.

In the European Patent Office, sequence listings must be included from the filing date. Late submission can be possible but typically involves additional fees and potential issues with the effective filing date.

In India, the Patent Office has its own evolving guidelines on biological sequences, and applicants filing next-generation sequencing patents in India should verify current requirements with local patent attorneys who specialize in biotechnology IP.

In China, the CNIPA follows international standards closely but may have additional disclosure requirements related to genetic resources, which is particularly relevant for NGS patents involving novel organisms or samples derived from biodiversity-rich regions.

Why Getting the Sequence Listing Right Protects Your NGS Innovation

A next-generation sequencing patent is only as strong as its disclosure. Courts and patent offices evaluate whether your invention is fully and clearly described, and the sequence listing is a core part of that disclosure. An incomplete or non-compliant sequence listing can narrow your patent scope, give competitors room to design around your claims, or in worse cases, invalidate the patent altogether.

Investing the time and resources to prepare a thorough, accurate, and fully compliant sequence listing is not just a regulatory obligation. It is a strategic decision that protects the full commercial value of your NGS innovation.

Final Thoughts

Preparing a compliant sequence listing for a next-generation sequencing patent is a detailed, technical process that sits at the intersection of biology, informatics, and patent law. With the global transition to WIPO ST.26, the bar for compliance has been raised. But with the right knowledge, tools, and professional support, you can navigate these requirements confidently and protect your genomic inventions with robust, enforceable patents.

Whether you are a biotech startup, a research institution, or a large pharmaceutical company, understanding how to properly disclose your NGS sequences in a patent application is a foundational skill in today’s competitive life sciences IP landscape.

We are the leading Patent Sequence Listing Company

At our Sequence Listing Company, we specialize exclusively in creating perfect patent sequence listings for biotechnology and pharmaceutical companies. Founded by patent attorneys and bioinformatics specialists with over 10 years of experience, we understand the critical intersection of scientific innovation and intellectual property protection. Our dedicated team has helped hundreds of companies successfully navigate the complex regulatory requirements of sequence listings across global patent offices. We combine technical precision with regulatory expertise to ensure your valuable innovations receive the protection they deserve without delays or complications.

Our Expertise

Specialized expertise in WIPO ST.25 and ST.26 standards
Customized solutions for complex biological sequences
Guaranteed compliance with patent office requirements
Rapid 24-48 hour turnaround time
Comprehensive quality assurance process

Trust Your Patent Sequence Listings to the Industry's Leading Experts

Effectual Knowledge Services pvt. ltd.

Effectual Services is an award-winning Intellectual Property (IP) management advisory & Consulting firm.